IS8493A - Notkun á rótigótíni við meðhöndlun og forvörn a dópamín taugafrumumissi - Google Patents

Notkun á rótigótíni við meðhöndlun og forvörn a dópamín taugafrumumissi

Info

Publication number: IS8493A
Authority: IS; Iceland
Prior art keywords: rotigotine; treatment; prevention; neurodegeneration; dopamine
Prior art date: 2003-12-24

Application number

IS8493A

Other languages

English (en)

Inventor

Scheller Dieter

Dressen Frank

Original Assignee

Schwarz Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-24

Filing date

2006-05-31

Publication date

2006-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34706587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-05-31 Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag

2006-05-31 Publication of IS8493A publication Critical patent/IS8493A/is

Links

KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title abstract 3
229960003179 rotigotine Drugs 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
229960003638 dopamine Drugs 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1
230000006378 damage Effects 0.000 abstract 2
210000004002 dopaminergic cell Anatomy 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
208000018737 Parkinson disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS8493A 2003-12-24 2006-05-31 Notkun á rótigótíni við meðhöndlun og forvörn a dópamín taugafrumumissi IS8493A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10361259A DE10361259A1 (de)	2003-12-24	2003-12-24	Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
PCT/EP2004/014655 WO2005063237A1 (de)	2003-12-24	2004-12-23	Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes

Publications (1)

Publication Number	Publication Date
IS8493A true IS8493A (is)	2006-05-31

Family

ID=34706587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8493A IS8493A (is)	2003-12-24	2006-05-31	Notkun á rótigótíni við meðhöndlun og forvörn a dópamín taugafrumumissi

Country Status (19)

Country	Link
EP (1)	EP1696904B1 (is)
JP (1)	JP5032125B2 (is)
KR (1)	KR101296561B1 (is)
CN (1)	CN1897935B (is)
AT (1)	ATE533484T1 (is)
AU (1)	AU2004308648B2 (is)
BR (1)	BRPI0418195A (is)
CA (1)	CA2547645C (is)
DE (1)	DE10361259A1 (is)
DK (1)	DK1696904T3 (is)
EA (1)	EA014418B1 (is)
ES (1)	ES2376881T3 (is)
IL (1)	IL175891A0 (is)
IS (1)	IS8493A (is)
NO (1)	NO20063276L (is)
NZ (1)	NZ547841A (is)
PL (1)	PL1696904T3 (is)
UA (1)	UA85858C2 (is)
WO (1)	WO2005063237A1 (is)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10361258A1 (de) *	2003-12-24	2005-07-28	Schwarz Pharma Ag	Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) *	2004-03-24	2006-07-06	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CN103175972B (zh) *	2005-10-21	2015-05-20	株式会社芳珂	特应性皮炎标记物及其利用技术
CN101147739B (zh)	2007-07-06	2010-12-08	北京康倍得医药技术开发有限公司	含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
EA017836B1 (ru)	2007-11-28	2013-03-29	ЮСиБи ФАРМА ГМБХ	Новая полиморфная форма ротиготина и способ ее получения
EP2201941A1 (de)	2008-12-29	2010-06-30	UCB Pharma GmbH	Pflaster-Herstellungstechnologie
EP2281559A1 (en)	2009-06-26	2011-02-09	UCB Pharma GmbH	Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CN104189912A (zh)	2009-12-22	2014-12-10	优时比制药有限公司	用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
IN2012DN06562A (is)	2010-02-05	2015-10-23	Ucb Pharma Gmbh
JP5748848B2 (ja)	2010-06-25	2015-07-15	ウーツェーベーファルマゲーエムベーハーＵｃｂＰｈａｒｍａＧｍｂｈ	窒素置換（ｓ）−５−アルコキシ−２−アミノテトラリン誘導体の分割方法
CN102379873B (zh) *	2010-09-06	2013-10-30	四川大学华西医院	一种急性全身性猴帕金森病模型及其药物筛选方法
EP2559435A1 (en)	2011-08-19	2013-02-20	UCB Pharma GmbH	Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2014037832A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment of epilepsy and neurological diseases
DE102012013439A1 (de)	2012-07-03	2014-01-23	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de)	2012-07-03	2014-01-09	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075823A1 (en)	2011-11-22	2013-05-30	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
JP2015519333A (ja)	2012-05-07	2015-07-09	セリックスビオプライヴェートリミテッド	神経疾患の治療のための組成物および方法
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
CN104603096A (zh)	2012-05-07	2015-05-06	塞利克斯比奥私人有限公司	用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
WO2013167992A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en)	2012-05-08	2016-02-23	Cellix Bio Private Limited	Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
WO2013168033A1 (en) *	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
WO2013168014A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of familial amyloid polyneuropathy
US9242939B2 (en)	2012-05-10	2016-01-26	Cellix Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en)	2012-05-10	2016-04-19	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en)	2012-05-10	2016-07-19	Cellix Bio Private Limited	Compositions and methods for the treatment of asthma and allergy
US9315461B2 (en)	2012-05-10	2016-04-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en)	2012-05-10	2016-05-24	Cellix Bio Private Limited	Compositions and methods for the treatment of fibromyalgia pain
US9403857B2 (en)	2012-05-10	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
WO2013168001A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of chronic pain
US9339484B2 (en)	2012-05-10	2016-05-17	Cellix Bio Private Limited	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9573927B2 (en)	2012-05-10	2017-02-21	Cellix Bio Private Limited	Compositions and methods for the treatment of severe pain
EP2852571A4 (en)	2012-05-23	2015-11-25	Cellix Bio Private Ltd	COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS
WO2013175376A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of local pain
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
JP6202287B2 (ja)	2012-05-23	2017-09-27	セリックスビオプライヴェートリミテッド	炎症性腸疾患の治療のための組成物及び方法
JP2015518854A (ja)	2012-05-23	2015-07-06	セリックスビオプライヴェートリミテッド	多発性硬化症の治療のための組成物および方法
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en)	2012-08-03	2015-11-17	Cellix Bio Private Limited	N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en)	2012-09-08	2017-06-06	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammation and lipid disorders
TW201431570A (zh)	2012-11-22	2014-08-16	Ucb Pharma Gmbh	用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en)	2013-06-04	2015-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of diabetes and pre-diabetes
US10046151B2 (en)	2013-07-03	2018-08-14	Lts Lohmann Therapie-Systeme, Ag	Transdermal therapeutic system with electronic component
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
WO2015177212A1 (en)	2014-05-20	2015-11-26	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system including an interface mediator
WO2015177209A1 (en)	2014-05-20	2015-11-26	Lts Lohmann Therapie-Systeme Ag	Method for adjusting the release of active agent in a transdermal delivery system
US11633367B2 (en)	2014-05-20	2023-04-25	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system containing rotigotine
NZ736131A (en)	2014-09-26	2019-04-26	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja)	2014-09-29	2020-05-27	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	多発性硬化症の治療のための組成物及び方法
EP3212626B1 (en)	2014-10-27	2018-11-07	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en)	2014-12-01	2018-04-03	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en)	2015-01-06	2021-10-27	Cellixbio Private Limited	Compositions and methods for the treatment of inflammation and pain
KR20190031314A (ko) *	2016-07-21	2019-03-25	산동 루예 파마슈티칼 컴파니 리미티드	로티고틴 베헤네이트, 그 제조 방법 및 그 용도
EP3854388B1 (de)	2020-01-24	2023-10-04	Luye Pharma Switzerland AG	Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber
CN112014193B (zh) *	2020-07-24	2021-06-15	武汉大学中南医院	一种新的fj染色方法和装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4564628A (en) *	1983-01-03	1986-01-14	Nelson Research & Development Co.	Substituted 2-aminotetralins
CO5111024A1 (es) *	1998-12-29	2001-12-26	Kimberly Clark Co	Composiciones de recubrimientos de polimero disparado por ion sobre peliculas de polimero sensibles al agua
SE9904723D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
JP4228048B2 (ja) *	2000-10-09	2009-02-25	ピーオーダブリューエムアールアイリミテッド	神経変性障害の検出方法
EP1344522A1 (en) *	2001-05-08	2003-09-17	Schwarz Pharma Ag	Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
DK1256340T3 (da) *	2001-05-08	2003-12-01	Sanol Arznei Schwarz Gmbh	Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
FR2828212B1 (fr) *	2001-08-03	2003-10-31	Aventis Pharma Sa	Methodes de diagnostic et de pronostic de la maladie de parkinson
EP1386605A1 (en) *	2002-07-30	2004-02-04	Schwarz Pharma Ag	Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) *	2003-12-24	2005-07-28	Schwarz Pharma Ag	Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) *	2004-03-24	2006-07-06	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms

2003
- 2003-12-24 DE DE10361259A patent/DE10361259A1/de not_active Withdrawn
2004
- 2004-12-23 KR KR1020067012204A patent/KR101296561B1/ko not_active Expired - Fee Related
- 2004-12-23 EP EP04804249A patent/EP1696904B1/de not_active Revoked
- 2004-12-23 CA CA2547645A patent/CA2547645C/en not_active Expired - Fee Related
- 2004-12-23 ES ES04804249T patent/ES2376881T3/es not_active Expired - Lifetime
- 2004-12-23 UA UAA200606332A patent/UA85858C2/uk unknown
- 2004-12-23 WO PCT/EP2004/014655 patent/WO2005063237A1/de not_active Ceased
- 2004-12-23 PL PL04804249T patent/PL1696904T3/pl unknown
- 2004-12-23 AT AT04804249T patent/ATE533484T1/de active
- 2004-12-23 EA EA200601227A patent/EA014418B1/ru not_active IP Right Cessation
- 2004-12-23 CN CN2004800386660A patent/CN1897935B/zh not_active Expired - Fee Related
- 2004-12-23 NZ NZ547841A patent/NZ547841A/en not_active IP Right Cessation
- 2004-12-23 BR BRPI0418195-6A patent/BRPI0418195A/pt not_active IP Right Cessation
- 2004-12-23 AU AU2004308648A patent/AU2004308648B2/en not_active Ceased
- 2004-12-23 DK DK04804249.3T patent/DK1696904T3/da active
- 2004-12-23 JP JP2006546071A patent/JP5032125B2/ja not_active Expired - Fee Related
2006
- 2006-05-24 IL IL175891A patent/IL175891A0/en unknown
- 2006-05-31 IS IS8493A patent/IS8493A/is unknown
- 2006-07-14 NO NO20063276A patent/NO20063276L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2007516996A (ja)	2007-06-28
BRPI0418195A (pt)	2007-06-19
HK1094538A1 (en)	2007-04-04
NO20063276L (no)	2006-08-30
CN1897935B (zh)	2010-05-26
KR20060109952A (ko)	2006-10-23
UA85858C2 (uk)	2009-03-10
NZ547841A (en)	2011-02-25
EA200601227A1 (ru)	2006-12-29
CA2547645A1 (en)	2005-07-14
JP5032125B2 (ja)	2012-09-26
WO2005063237A1 (de)	2005-07-14
IL175891A0 (en)	2006-10-05
DK1696904T3 (da)	2012-02-13
AU2004308648B2 (en)	2010-12-16
PL1696904T3 (pl)	2012-04-30
DE10361259A1 (de)	2005-07-28
CN1897935A (zh)	2007-01-17
ATE533484T1 (de)	2011-12-15
EP1696904B1 (de)	2011-11-16
AU2004308648A1 (en)	2005-07-14
EA014418B1 (ru)	2010-12-30
EP1696904A1 (de)	2006-09-06
KR101296561B1 (ko)	2013-08-13
ES2376881T3 (es)	2012-03-20
CA2547645C (en)	2013-07-16

Publication	Publication Date	Title
IS8493A (is)	2006-05-31	Notkun á rótigótíni við meðhöndlun og forvörn a dópamín taugafrumumissi
TW200635582A (en)	2006-10-16	Medicaments for the treatment or prevention of fibrotic diseases
IS2517B (is)	2009-06-15	Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EP1945628A4 (en)	2010-06-02	NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY, AND THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER DISEASE
MX374396B (es)	2025-03-06	Rocio de fentanilo sublingual.
NO20064792L (no)	2006-10-23	Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
MX2007001679A (es)	2007-05-23	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
UA92584C2 (ru)	2010-11-25	Применение мелоксикама для лечения респираторных заболеваний у свиней
BRPI0407662A (pt)	2006-03-01	derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
MX2010006204A (es)	2011-03-16	Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
PL2244703T3 (pl)	2012-05-31	Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
DK1781277T3 (da)	2012-05-07	Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
MX2009011999A (es)	2009-11-19	Extruidos con enmascaramiento del sabor mejorado.
TW200637544A (en)	2006-11-01	Medicaments for the treatment or prevention of fibrotic diseases
TW200716152A (en)	2007-05-01	Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
TW200635595A (en)	2006-10-16	Medicaments for the treatment of prevention of fibrotic diseases
ZA200707486B (en)	2009-02-25	Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
WO2007017146A3 (en)	2007-07-26	Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2007025229A3 (en)	2007-08-16	Compositions and their uses directed to hsp27
UA86873C2 (en)	2009-05-25	SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
ATE479423T1 (de)	2010-09-15	Vorrichtung für die topische anwendung des medizinischen ozons zur behandlung von erkrankungen der mundhöhle
UA99093C2 (ru)	2012-07-25	Применение фенофибрата или его производного для лечения диабетической ретинопатии
UA87224C2 (ru)	2009-06-25	Применение 24-нор-урсодеоксихолевой кислоты для лечения холестатических заболеваний печени
TW200700072A (en)	2007-01-01	Method for treatment of hepatic cancer
HN2002000271A (es)	2002-11-05	2,5 diamidoindoles sustituidos y su utilizacion.